<DOC>
	<DOCNO>NCT02916706</DOCNO>
	<brief_summary>This study design prospective , multi-centre , parallel group , double-blind randomize , placebo-controlled , phase 3 clinical study evaluate efficacy safety MP-513 ( Teneligliptin ) .</brief_summary>
	<brief_title>Efficacy Safety Teneligliptin Chinese Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>A sign date informed consent form obtain subject , accordance International Conference Harmonisation guideline Good Clinical Practice ( ICH GCP ) , screen study related procedure take place . The subject age ≥18 year signature inform consent form . Hospitalization status : outpatient . The subject document diagnosis type 2 diabetes mellitus least 3 month screen visit ( Day 28 ) . The subject undergoing diet exercise therapy , diet exercise regimen change least 8 consecutive week screen visit ( Day 28 ) . Subjects exercise due complication limit criterion . The subject 's glycosylated fraction haemoglobin ( HbA1c ) ≥ 7.0 % &lt; 10.0 % screen visit ( Day 28 ) Day 14 . The subject history type 1 diabetes mellitus secondary form diabetes . The subject receive insulin within 1 year prior screen visit ( Day 28 ) , exception insulin therapy hospitalization insulin therapy medical condition require hospitalization ( &lt; 2 week ' duration ) . The subject receive antidiabetic drug within 8 week prior screen visit ( Day 28 ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>